Achieving Consensus in Breast Cancer Management across Scotland

Thomas Denholm – Programme Manager, SCN, NSS Dr Frances Yuille – Breast CMP Lead, NHS Lothian Dr. Noelle O'Rourke – National Clinical Lead, SCN





Recovery and Redesign: An Action Plan for Cancer Services







December 2020 - March 2023

Scottish Government 2021

Mandate to create Scottish Cancer Network. Objectives:

Develop and operate a national system for the production and review of

Clinical Management Guidelines.

Oversee and drive improvement of • existing National Managed Clinical Networks

Cancer Plan 2023 SCN Endorsement



Cancer Action Plan for Scotland 2023-2026



Guidelines: Evidence, Consensus and Audit

SIGN guidelines (NATIONAL)

Robust evidence based process.

Gold standard graded recommendations

Resource intensive +++

Primary breast cancer 2013, Mets 2004 Out of date +++ Quality Performance Indicators (NATIONAL)

Consensus Process

Standards for only new patients/treatment paths

Used for annual audit and performance assessment

Updated every 3y ongoing 2022 NCA public access

CMGs

(REGIONAL)

Regional consensus

SCAN not public Oncology quality system

WOSCAN not public Intranet

Different content, format, detail and updates across 3 regions.





Clinical Management Pathways

What CMPs aim to be

- Description of the best practice
- Clinical consensus
- Represent Once for Scotland approach
- Designed for healthcare
 professionals

What CMPs are NOT

- Mandate
- Replacement for clinical decision-making process
- Documents restricted by capacity constraints
- Documents aimed at patients

Breast Cancer Clinical Management Pathway



Subgroups

- Clinical/ technical
- Available to clinicians
- Aligned with QPIs
- Frequent updates to reflect practice

Purpose

A pan-Scotland pathway from diagnosis to follow up/end of life care

Describe best-practiceGuide to support shared decision making

Patient Pathway

Principles

- Developed with consensus
 - wide input and engagement
- Uniform template across all tumour groups
- Dynamic, pragmatic, reflects real world practice


Patient Pathway

- 'Translation' of
- professional CMP
- Based on patient
- involvement
- Available on public platform





Consensus – How?



Achieving Consensus on Breast Cancer Radiotherapy across Scotland

| | | Aberdeen | Edinburgh | Glasgow | Inverness | |
|---------------|---------------------|--|---|--|---|--|
| Chest Wall | Consensus | Radiotherapy can be recommended to patients with a score of >/=3. (Addenbrooke's H ospital System)** | T3/T4 ≥4 nodes inANC Involved margins 1-3 nodes in ANC with one or more other high risk feature: grade 3, LVI positive, ER negative, HER2 positive | T3/T4 Inadequate margin(< 1mm) Axillary LN involvement (?any number) Residual disease post surgery(?is this different to inadequate margin) Initially inoperable or locally advanced tumour treated with NAC | T3/4 4 or more nodes positive +ve margins Consider PMRT for close/positive margins, age < =40 years, 2 or 3 axillary macro metastases, LVI +, Grade 3, ER – Her2 +, or Triple negative breast cancer | |
| | Discussion Point | Agreement on T3/T4, 4 or more nodes in ANC, positive margins Need discussion re 1-3 nodes | | | | |

Which patients benefit from 'dose-dense' chemotherapy ?

Achieving national Consensus

- Dose-dense approach varied across Scotland before CMP
- Initial meta-analysis had participants treated 1985-2011 so, targeted therapies were not routinely used.
- Data from two trials indicated that quality of life was worse during treatment with dose-intense therapy
- Few women (<2%) included in the relevant trials were aged 70 or older.
- Debates on relative benefits in Scottish population versus risks of toxicity

• SCN invited HIS to undertake full evidence review of topic

Recommendations

- Dose-dense is the recommended default for adjuvant chemotherapy in high-risk early breast cancer.
- Treatment decisions should be based on shared decision making following assessment of risk of recurrence and taking account of patient fitness, comorbidities and individual preferences.
- CMOP collaboration to follow on.






SHTG Recommendations October 2023

In response to an enquiry from the Scottish Cancer Network

Tumour profiling tests to guide adjuvant chemotherapy decisions for patients with early breast cancer

Recommendations for NHSScotland

Consultation & Review – How ?



Clinical Management Pathways for Cancer

Right Decision Service (RDS) Hosted by HIS


Live launch September 2023 Breast, Lung, Adult Neuro

Email the Scottish Cancer Network team at nss.scottishcancernetwork@nhs.scot When your registration is confirmed, you will be sent the current password with details on how to access.

Supportive Care Guidance now out for breast, lung and adult neuro


Patient facing website; breast content launch in progress

CMPs for Prostate Cancer and Head and Neck cancer underway




RDS Analytics (as at 21/02/2023)

| Operating System | Number of Users |
|---------------------|--------------------|
| Windows | 702 |
| iOS | 34 |
| Mac | 31 |
| Android | 21 |




Patient involvement



Research scale

- Desk research analysing Scottish Cancer Patient Experience Survey, Care Opinions and academic resources;
- Online survey (over 100 responses);
- Online survey supported by project team attending 5 cancer centres and collating responses in person;
- Focus groups with 3rd sector and NHS Professionals (~20 attendees);
- Focus groups with patients, carers and family members of cancer patients (~50 attendees);
- Offline review (~20 reviews by NHS professionals and 3rd sector and ~ 10 by patients, carers and family members);

Linking patient and clinical content



| SCOTLAND Cancer Patient Information | | Search | Q |
|---|---|---|--------------------------|
| Home Useful Resources | Cancer Pathway | Cancer Specific Information | Contact us |
| Home > Cancer specific information > Brea | ast Cancer | | |
| Breast Cancer | | Cancer specific | c |
| Please see below specific pages coveri Cancer treatment journey. | Please see below specific pages covering key aspects of the Breast Cancer treatment journey. | | |
| <u>Diagnosis and</u> Imaging <u>(X-rays and</u> <u>Scans)</u> | <u>Pathology</u> | <u>Familial (Genet</u> <u>Radiotherapy</u> <u>Surgery</u> <u>Pathology</u> <u>Systematic Ant</u> <u>(SACT)</u> <u>Useful Resource</u> | <u>ti Cancer Therapy</u> |
| | | Lung Cancer Adult Brain Cancer | |
| <u>Surgery</u> | <u>Radiotherapy</u> | | |
| | | | |
| <u>Familial (Genetics)</u> | <u>Systematic Anti-</u> <u>Cancer Therapy</u> <u>(SACT)</u> | | |
| | | | |

Updates and Medicines Governance

- Continuing progress of CMPs to describe full treatment pathway for other tumours
- 3 yearly updates with editorial team overseeing interim changes
- Consensus driven approach to SACT with phased move from CMGs to CMPs
- Local CEPAS infrastructure, SACT protocols and formulary processes remain until national processes enable streamlining
- Collaboration with ongoing national reviews of medicines governance, and regional implementation and capacity

Implementation of Clinical Management Pathways

Consistent consensus based practice across Scotland

Reduced duplication of effort and professional time

Programme support for dynamic changes and updates

HIS supported evidence reviews

Scope to reduce capacity and financial challenges / Realistic medicine

NOT a mandate for immediate implementation but supports planning

Guidance positioned nationally alongside SIGN

Benefits of a National Process

| For Patients | Standardised carePromoting equity of access | | |
|----------------|--|--|--|
| | | | |
| For Clinicians | Assistance with complex pathways Reassurance that care is comparable to other sites | | |
| | | | |
| For Scotland | Dynamic new resource Cooperation and communication between networks | | |

With huge thanks to all the patients and professionals who have collaborated to make the CMPs happen.

